New therapy targets for metastatic prostate cancer
Official title: Combining Multi-omics Analysis and Organoid Models to Search for Novel Therapy Target in Metastatic Prostate Cancer
Run by Fudan University · NCT05577689 · Data updated 2026-11-12
This project will use multi-omics sequencing and patient tumor models to try to find new drug targets for men with metastatic or castration-resistant prostate cancer.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | Men only |
| Enrollment | 100 (estimated) |
| Sponsor | Fudan University Academic / other |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Status | Recruiting |
| Started | August 1, 2023 |
| Main results expected | December 1, 2026 |
| Study ends | December 1, 2028 |
| Registry record updated | June 5, 2025 |
| Trial ID | NCT05577689 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are men with histologically confirmed metastatic prostate cancer who can undergo surgery or biopsy and can provide informed consent.
✕Probably not a fit
Patients without prostate cancer, those who cannot provide an accessible tissue sample or cannot give informed consent, and men with only localized disease are unlikely to benefit from this project.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Researchers will collect tumor tissue from men with metastatic prostate cancer and perform multi-omics sequencing to map genetic, transcriptomic, and other molecular features. Selected molecular candidates will be tested in patient-derived organoids and animal models to see which changes drive metastasis or drug resistance. The organoid and animal platforms are intended to link molecular findings to functional evidence that a target might be druggable. Findings will be used to build a translational research system aimed at identifying interventions for mCRPC.
Why it matters
Potential benefit: If successful, this work could identify new drug targets that lead to more effective treatments for men with metastatic castration-resistant prostate cancer.
How similar studies have gone: Previous multi-omics efforts and organoid models have shown promise in identifying candidate targets and mechanisms, but translation to new approved therapies has been limited to date.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Histologically confirmed prostate cancer 2. metastatic disease confirmed by image examination 3. Patients who can undergo surgery or biopsy for prostate cancer 4. Able to provide informed consent Exclusion Criteria: 1. Patients diagnosed with other types of cancer besides prostate cancer 2. Not accessible to surgery sample 3. Patients fail to provide informed consent 4. Other situation that researchers think are unsuitable for this study
Where it's running
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China Recruiting
Study contacts
- Study coordinator: Yao Zhu
- Email: mailzhuyao@163.com
- Phone: +86 15001818005
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Combining M9241 with Docetaxel for Prostate Cancer Treatment
This study is testing if the combination of the drug M9241 with docetaxel can help men with advanced prostate cancer live longer and feel better.
-
Effectiveness and Safety of Disease-Modifying Therapy for Alzheimer's Disease in Real World Practice
This study will look at real-world safety and effectiveness of disease-modifying therapy (DMT) in adults with MCI or Alzheimer's dementia by comparing those who receive DMT in routine care to those who do not.
-
ctDNA methylation-guided adjuvant therapy after removing colorectal liver metastases
This trial tests whether using a blood test that detects ctDNA methylation after surgery can guide adjuvant therapy for patients who had colorectal cancer spread to the liver and were operated on with no remaining disease.
-
China HEAD: a large community study on healthy aging and dementia
This study tests whether collecting health, imaging, and biospecimen data from adults in China can help predict who will develop Alzheimer’s disease and related dementias.
-
Becotatug Vedotin plus Pucotenlimab for EGFR-positive metastatic colorectal cancer
This study tests whether combining becotatug vedotin with pucotenlimab can shrink tumors in adults with colorectal cancer that has returned or spread after at least two prior treatments and whose tumors express EGFR.
-
ctDNA-Guided Immunotherapy for dMMR/MSI-H Colon Cancer
This study tests whether tracking ctDNA can guide neoadjuvant immunotherapy and surgical decisions for people with dMMR/MSI-H colon cancer, using PD-1 inhibitors first and adding CTLA-4 inhibitors if ctDNA remains detectable.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.